Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1low mouse model

Published:September 30, 2022DOI:


      • We demonstrated that treatment with the antibody RB40.34, which targets murine P-selectin, and ruxolitinib in combination is more effective than either drug alone in rescuing the phenotype expressed by the Gata1low mouse model of myelofibrosis.
      • The two drugs in combination reduced fibrosis, bone deposition, and neoangiogenesis while restoring hematopoiesis in the bone marrow and reducing hematopoiesis and restoring the architecture of the spleen of Gata1low mice.
      • Mechanistically, the two drugs in combination may have exerted these effects by reducing the TGF-β and CXCL1 content, the two proinflammatory cytokines supposed to be the driver of fibrosis, in the bone marrow.
      • These data provide preclinical evidence that P-selectin antibodies and ruxolitinib in combination may be more effective than ruxolitinib alone to treat myelofibrosis.
      The bone marrow (BM) and spleen from patients with myelofibrosis (MF), as well as those from the Gata1low mouse model of the disease contain increased number of abnormal megakaryocytes. These cells express high levels of the adhesion receptor P-selectin on their surface, which triggers a pathologic neutrophil emperipolesis, leading to increased bioavailability of transforming growth factor-β (TGF-β) in the microenvironment and disease progression. With age, Gata1low mice develop a phenotype similar to that of patients with MF, which is the most severe of the Philadelphia-negative myeloproliferative neoplasms. We previously demonstrated that Gata1low mice lacking the P-selectin gene do not develop MF. In the current study, we tested the hypothesis that pharmacologic inhibition of P-selectin may normalize the phenotype of Gata1low mice that have already developed MF. To test this hypothesis, we have investigated the phenotype expressed by aged Gata1low mice treated with the antimouse monoclonal antibody RB40.34, alone and also in combination with ruxolitinib. The results indicated that RB40.34 in combination with ruxolitinib normalizes the phenotype of Gata1low mice with limited toxicity by reducing fibrosis and the content of TGF-β and CXCL1 (two drivers of fibrosis in this model) in the BM and spleen and by restoring hematopoiesis in the BM and the architecture of the spleen. In conclusion, we provide preclinical evidence that treatment with an antibody against P-selectin in combination with ruxolitinib may be more effective than ruxolitinib alone to treat MF in patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Experimental Hematology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zahr AA
        • Salama ME
        • Carreau N
        • et al.
        Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
        Haematologica. 2016; 101: 660-671
        • Barbui T
        • Tefferi A
        • Vannucchi AM
        • et al.
        Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
        Leukemia. 2018; 32: 1057-1069
        • Marcellino BK
        • Verstovsek S
        • Mascarenhas J.
        The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication.
        Clin Lymphoma Myeloma Leuk. 2020; 20: 415-421
        • Dunbar AJ
        • Rampal RK
        • Levine R.
        Leukemia secondary to myeloproliferative neoplasms.
        Blood. 2020; 136: 61-70
        • Vainchenker W
        • Constantinescu SN.
        JAK/STAT signaling in hematological malignancies.
        Oncogene. 2013; 32: 2601-2613
        • Malara A
        • Abbonante V
        • Zingariello M
        • Migliaccio A
        • Balduini A.
        Megakaryocyte contribution to bone marrow fibrosis: many arrows in the quiver.
        Mediterr J Hematol Infect Dis. 2018; 10e2018068
        • Schmitt A
        • Jouault H
        • Guichard J
        • Wendling F
        • Drouin A
        • Cramer EM.
        Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis.
        Blood. 2000; 96: 1342-1347
        • Centurione L
        • Di Baldassarre A
        • Zingariello M
        • et al.
        Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice.
        Blood. 2004; 104: 3573-3580
        • Vannucchi AM
        • Pancrazzi A
        • Guglielmelli P
        • et al.
        Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.
        Am J Pathol. 2005; 167: 849-858
        • Gilles L
        • Arslan AD
        • Marinaccio C
        • et al.
        Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.
        J Clin Invest. 2017; 127: 1316-1320
        • Crispino JD
        • Weiss MJ.
        Erythro-megakaryocytic transcription factors associated with hereditary anemia.
        Blood. 2014; 123: 3080-3088
        • Vannucchi AM
        • Bianchi L
        • Cellai C
        • et al.
        Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).
        Blood. 2002; 100: 1123-1132
        • Woods B
        • Chen W
        • Chiu S
        • et al.
        Activation of JAK/STAT signaling in megakaryocytes sustains myeloproliferation in vivo.
        Clin Cancer Res. 2019; 25: 5901-5912
        • Zhang Y
        • Lin CHS
        • Kaushansky K
        • Zhan H.
        JAK2V617F megakaryocytes promote hematopoietic stem/progenitor cell expansion in mice through thrombopoietin/MPL signaling.
        Stem Cells. 2018; 36: 1676-1684
        • Ciurea SO
        • Merchant D
        • Mahmud N
        • et al.
        Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.
        Blood. 2007; 110: 986-993
        • Campanelli R
        • Rosti V
        • Villani L
        • et al.
        Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.
        Cytokine. 2011; 53: 100-106
        • Chagraoui H
        • Komura E
        • Tulliez M
        • Giraudier S
        • Vainchenker W
        • Wendling F.
        Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.
        Blood. 2002; 100: 3495-3503
        • Gastinne T
        • Vigant F
        • Lavenu-Bombled C
        • et al.
        Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
        Exp Hematol. 2007; 35: 64-74
        • Zingariello M
        • Martelli F
        • Ciaffoni F
        • et al.
        Characterization of the TGF-beta1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
        Blood. 2013; 121: 3345-3363
        • Varricchio L
        • Iancu-Rubin C
        • Upadhyaya B
        • et al.
        TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
        JCI Insight. 2021; 6e145651
        • Gerds AT
        • Vannucchi AM
        • Passamonti F
        • et al.
        Duration of response to luspatercept in patients (Pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF) – updated data from the Phase 2 ACE-536-MF-001 Study.
        Blood. 2020; 136: 47-48
        • Zetterberg E
        • Verrucci M
        • Martelli F
        • et al.
        Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis.
        Platelets. 2014; 25: 539-547
        • Moore KL
        • Stults NL
        • Diaz S
        • et al.
        Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells.
        J Cell Biol. 1992; 118: 445-456
        • Evangelista V
        • Manarini S
        • Sideri R
        • et al.
        Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule.
        Blood. 1999; 93: 876-885
        • Thiele J
        • Lorenzen J
        • Manich B
        • Kvasnicka HM
        • Zirbes TK
        • Fischer R.
        Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis.
        Acta Haematol. 1997; 97: 137-143
        • Zingariello M
        • Ruggeri A
        • Martelli F
        • et al.
        A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1low mouse model of myelofibrosis.
        Am J Blood Res. 2015; 5: 34-61
        • Spangrude GJ
        • Lewandowski D
        • Martelli F
        • et al.
        P-Selectin sustains extramedullary hematopoiesis in the Gata1low model of myelofibrosis.
        Stem Cells. 2016; 34: 67-82
        • Ceglia I
        • Dueck AC
        • Masiello F
        • et al.
        Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.
        Exp Hematol. 2016; 44: 1138-1155
        • Ataga KI
        • Kutlar A
        • Kanter J
        • et al.
        Crizanlizumab for the prevention of pain crises in sickle cell disease.
        N Engl J Med. 2017; 376: 429-439
        • Embury SH
        • Matsui NM
        • Ramanujam S
        • et al.
        The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo.
        Blood. 2004; 104: 3378-3385
        • Martelli F
        • Ghinassi B
        • Panetta B
        • et al.
        Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds.
        Blood. 2005; 106: 4102-4113
        • Zingariello M
        • Sancillo L
        • Martelli F
        • et al.
        The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature.
        Blood Cancer J. 2017; 7: 1-11
        • Oguro H
        • Ding L
        • Morrison SJ.
        SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors.
        Cell Stem Cell. 2013; 13: 102-116
        • Schneider CA
        • Rasband WS
        • Eliceiri KW.
        NIH Image to ImageJ: 25 years of image analysis.
        Nat Methods. 2012; 9: 671-675
        • Zingariello M
        • Verachi P
        • Gobbo F
        • et al.
        Resident self-tissue of proinflammatory cytokines rather than their systemic levels correlates with development of myelofibrosis in Gata1low mice.
        Biomolecules. 2022; 12: 234-260
        • Vyas P
        • Ault K
        • Jackson CW
        • Orkin SH
        • Shivdasani RA.
        Consequences of GATA-1 deficiency in megakaryocytes and platelets.
        Blood. 1999; 93: 2867-2875
        • Fletcher K
        • Myant NB.
        Biotin in the synthesis of fatty acid and cholesterol by mammalian liver.
        Nature. 1960; 188: 585
        • Massagué J
        • Blain SW
        • Lo RS.
        TGFbeta signaling in growth control, cancer, and heritable disorders.
        Cell. 2000; 103: 295-309
        • Migliaccio AR
        • Martelli F
        • Verrucci M
        • et al.
        Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation.
        Blood. 2009; 114: 2107-2120
        • Li L
        • Kim JH
        • Lu W
        • et al.
        HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
        Blood. 2022; 139: 2797-2815
        • Garimella R
        • Kacena MA
        • Tague SE
        • Wang J
        • Horowitz MC
        • Anderson HC.
        Expression of bone morphogenetic proteins and their receptors in the bone marrow megakaryocytes of GATA-1(low) mice: a possible role in osteosclerosis.
        J Histochem Cytochem. 2007; 55: 745-752
        • Kacena MA
        • Shivdasani RA
        • Wilson K
        • et al.
        Megakaryocyte–osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2.
        J Bone Miner Res. 2004; 19: 652-660
        • Karagianni A
        • Ravid K.
        Myeloproliferative disorders and its effect on bone homeostasis: the role of megakaryocytes.
        Blood. 2022; 139: 3127-3137
        • Stavnichuk M
        • Komarova SV.
        Megakaryocyte-bone cell interactions: lessons from mouse models of experimental myelofibrosis and related disorders.
        Am J Cell Physiol. 2022; 322: C177-C184
        • Perner F
        • Perner C
        • Ernst T
        • Heidel FH.
        Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation.
        Cells. 2019; 8: 854-873
        • Steiniger BS.
        Human spleen microanatomy: why mice do not suffice.
        Immunology. 2015; 145: 334-346
        • Sun S
        • Jin C
        • Si J
        • et al.
        Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis.
        Blood. 2021; 138: 1211-1224
        • Ghinassi B
        • Sanchez M
        • Martelli F
        • et al.
        The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor.
        Blood. 2007; 109: 1460-1471
        • Foreman KE
        • Vaporciyan AA
        • Bonish BK
        • et al.
        C5a-induced expression of P-selectin in endothelial cells.
        J Clin Invest. 1994; 94: 1147-1155
        • Verachi P
        • Gobbo F
        • Martelli F
        • et al.
        The CXCR1/CXCR2 inhibitor reparixin alters the development of myelofibrosis in the Gata1low mice.
        Front Oncol. 2022; 12: 853484-853498
        • Emadi S
        • Clay D
        • Desterke C
        • et al.
        IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis.
        Blood. 2005; 105: 464-473
        • McDevitt MA
        • Fujiwara Y
        • Shivdasani RA
        • Orkin SH.
        An upstream, DNase I hypersensitive region of the hematopoietic-expressed transcription factor GATA-1 gene confers developmental specificity in transgenic mice.
        Proc Natl Acad Sci U S A. 1997; 94: 7976-7981
        • Wen QJ
        • Yang Q
        • Goldenson B
        • et al.
        Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
        Nat Med. 2015; 21: 1473-1480
        • Kramer F
        • Dernedde J
        • Mezheyeuski A
        • Tauber R
        • Micke P
        • Kappert K.
        Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis.
        Haematologica. 2020; 105: 2083-2094
        • Corey SJ
        • Jha J
        • McCart EA
        • et al.
        Captopril mitigates splenomegaly and myelofibrosis in the Gata1low murine model of myelofibrosis.
        J Cell Mol Med. 2018; 22: 4274-4282
        • Leiva O
        • Ng SK
        • Matsuura S
        • et al.
        Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice.
        Int J Hematol. 2019; 110: 699-6708
        • Lucijanic M
        • Pejsa V
        • Jaksic O
        • et al.
        The degree of anisocytosis predicts survival in patients with primary myelofibrosis.
        Acta Haematol. 2016; 136: 98-100
        • Bommireddy R
        • Saxena V
        • Ormsby I
        • et al.
        TGF-β1 regulates lymphocyte homeostasis by preventing activation and subsequent apoptosis of peripheral lymphocytes.
        J Immunol. 2003; 170: 4612-4622
        • Batlle E
        • Massagué J.
        Transforming growth factor-β signaling in immunity and cancer.
        Immunity. 2019; 50: 924-940
        • Mukaida N.
        Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation.
        Int J Hematol. 2000; 72 (DOI not available): 391-398
      1. Palomino DCT, Marti LC. Chemokines and immunity. Einstein (São Paulo). 2015;13:469–473.

        • Pariser DN
        • Hilt ZT
        • Ture SK
        • et al.
        Lung megakaryocytes are immune modulatory cells.
        J Clin Invest. 2021; 131e137377
        • Wang H
        • He J
        • Xu C
        • et al.
        Decoding human megakaryocyte development.
        Cell Stem Cell. 2021; 28 (e8): 535-549
        • Yeung AK
        • Villacorta-Martin C
        • Hon S
        • Rock JR
        • Murphy GJ.
        Lung megakaryocytes display distinct transcriptional and phenotypic properties.
        Blood Adv. 2020; 4: 6204-6217
        • Abbonante V
        • Di Buduo CA
        • Gruppi C
        • et al.
        Thrombopoietin/TGF-β1 loop regulates megakaryocyte extracellular matrix component synthesis.
        Stem Cells. 2016; 34: 1123-1133
        • Malara A
        • Currao M
        • Gruppi C
        • et al.
        Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin.
        Stem Cells. 2014; 32: 926-937